CA2369263A1 - Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus - Google Patents

Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus Download PDF

Info

Publication number
CA2369263A1
CA2369263A1 CA002369263A CA2369263A CA2369263A1 CA 2369263 A1 CA2369263 A1 CA 2369263A1 CA 002369263 A CA002369263 A CA 002369263A CA 2369263 A CA2369263 A CA 2369263A CA 2369263 A1 CA2369263 A1 CA 2369263A1
Authority
CA
Canada
Prior art keywords
agent
apoptosis inducing
apoptosis
therapeutic agent
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002369263A
Other languages
English (en)
Inventor
Jessie Au
Guillaume Wientjes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2369263A1 publication Critical patent/CA2369263A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne, au moins en partie, des méthodes qui améliorent la diffusion d'agents thérapeutiques, tels que des macromolécules ou des médicaments, à l'intérieur de tissus, tels que des tissus solides ou des tumeurs. La méthode utilise initialement un agent inducteur d'apoptose, tel que le paclitaxel, administré en doses propres à créer des canaux à l'intérieur du tissu et à y améliorer la pénétration d'agents thérapeutiques. Les méthodes classiques de traitement des tissus sont souvent peu efficaces parce que les agents thérapeutiques ne sont pas diffusés à l'intérieur du tissu. L'utilisation des méthodes et des compositions de l'invention permet de diffuser des agents thérapeutiques à l'intérieur du tissu.
CA002369263A 1999-04-09 2000-04-07 Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus Abandoned CA2369263A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12867499P 1999-04-09 1999-04-09
US60/128,674 1999-04-09
PCT/US2000/009329 WO2000061141A2 (fr) 1999-04-09 2000-04-07 Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus

Publications (1)

Publication Number Publication Date
CA2369263A1 true CA2369263A1 (fr) 2000-10-19

Family

ID=22436437

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002369263A Abandoned CA2369263A1 (fr) 1999-04-09 2000-04-07 Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus

Country Status (5)

Country Link
EP (1) EP1171118A2 (fr)
JP (1) JP2003524624A (fr)
AU (1) AU777620B2 (fr)
CA (1) CA2369263A1 (fr)
WO (1) WO2000061141A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ES2272768T3 (es) * 2001-10-03 2007-05-01 Celator Pharmaceuticals Inc Composiciones para la administracion de combinaciones de farmacos.
CA2383259A1 (fr) 2002-04-23 2003-10-23 Celator Technologies Inc. Composes synergiques
CA2469623C (fr) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition pour la conservation de virus
JP2004277379A (ja) * 2003-03-18 2004-10-07 Medicos Hirata:Kk 細胞死誘発ドラッグデリバリーシステム
CN102697737B (zh) * 2003-04-03 2014-03-19 杰西.L.-S.奥 负载肿瘤靶向药物的颗粒
US8043631B2 (en) * 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
BRPI0502497A (pt) * 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
WO2009116556A1 (fr) * 2008-03-19 2009-09-24 富士フイルム株式会社 Composition pharmaceutique pour injection
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
EP2481396A4 (fr) * 2009-09-21 2014-03-05 Jw Pharmaceutical Corp Nanoparticules d'oxaliplatine et leur procédé de préparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2136091A1 (fr) * 1992-05-20 1993-11-25 Daniel S. Martin Combinaisons medicamenteuses chimiotherapeutiques
AU693821B2 (en) * 1993-11-18 1998-07-09 Sirtex Medical Limited Controlled release preparation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5900429A (en) * 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
ATE278397T1 (de) * 1997-03-31 2004-10-15 Boston Scient Ltd Verwendung von cytoskelettinhibitoren zur vorbeugung der restenose
SK182599A3 (en) * 1997-06-20 2000-07-11 Baker Norton Pharma Soluble prodrugs of paclitaxel
JPH11269065A (ja) * 1998-03-19 1999-10-05 Microbial Chem Res Found 癌細胞のアポトーシス耐性の克服剤
JPH11322602A (ja) * 1998-05-13 1999-11-24 Kazuo Umezawa 転写因子ＮＦκＢ活性化阻害剤

Also Published As

Publication number Publication date
WO2000061141A3 (fr) 2001-03-01
WO2000061141A2 (fr) 2000-10-19
EP1171118A2 (fr) 2002-01-16
JP2003524624A (ja) 2003-08-19
AU4214200A (en) 2000-11-14
AU777620B2 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
US7217735B1 (en) Methods and compositions for enhancing delivery of therapeutic agents to tissues
Dave et al. Lipid-polymer hybrid nanoparticles: Synthesis strategies and biomedical applications
Papa et al. Ultrasound-sensitive nanoparticle aggregates for targeted drug delivery
Kabanov et al. New technologies for drug delivery across the blood brain barrier
Singh et al. Nanoparticle-based targeted drug delivery
Jain et al. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery
Gao et al. UEA I-bearing nanoparticles for brain delivery following intranasal administration
EP0740548B1 (fr) Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
Abdelaziz et al. Inhalable lactoferrin/chondroitin-functionalized monoolein nanocomposites for localized lung cancer targeting
Kasinathan et al. Strategies for drug delivery to the central nervous system by systemic route
US20040038406A1 (en) Nanoparticle delivery systems and methods of use thereof
Vauthier A journey through the emergence of nanomedicines with poly (alkylcyanoacrylate) based nanoparticles
EP2106806A1 (fr) Nanoparticules pour la livraison ciblée d'agents actifs vers les poumons
AU777620B2 (en) Methods and compositions for enhancing delivery of therapeutic agents to tissues
CA2623293A1 (fr) Nanoparticules pour administration ciblee de principes actifs
Lahkar et al. Surface modified polymeric nanoparticles for brain targeted drug delivery
Ahmad et al. A comprehensive review on targeted drug delivery system
Sarwar et al. Oral delivery and enhanced efficacy of antimonal drug through macrophage-guided multifunctional nanocargoes against visceral Leishmaniasis
Thakur et al. Recent trends in targeted drug delivery
Agrawal et al. A snapshot on polymeric micelles as a carrier for drug delivery
KR20210053881A (ko) 살리노마이신을 포함하는 폴리머 나노입자
TWI472341B (zh) 寡聚物奈米顆粒複合體釋放系統
US20250295606A1 (en) Biosoluble polymer or particle for delivery of an active agent and a method for the production
Pathak et al. Pharmaceutical applications of nanoparticulate drug-delivery systems
Andrieux et al. Polymeric nanoparticles for drug delivery

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead